Experimental Peanut Allergy Drug Ready For FDA Review

An experimental peanut allergy treatment is ready for U.S. Food and Drug Administration review. 

According to research published in The New England Journal of MedicineA phase three trial included 551 people, most ages 4 to 17 with a history of life-threatening reactions after eating peanuts. Participants were given the experimental drug derived from peanuts daily over the course of several months. 

Two-thirds of the children in the study were able to eat the equivalent of two peanuts without any symptoms after following the months-long experimental treatment regimen, the researchers found.

"We're excited about the potential to help children and adolescents with peanut allergy protect themselves against accidentally eating a food with peanut in it." said, Allergist and co-author, Stephen Tilles.

According to the Centers for Disease Control and Prevention, Allergies are the 6th leading cause of chronic illness in the U.S. with an annual cost in excess of $18 billion. More than 50 million Americans suffer from allergies each year.

Premier Diversity Employers

Lists by Topic

see all